Back to Results
First PageMeta Content
Pyrimidines / Gastrointestinal cancer / Gastrointestinal stromal tumor / Imatinib / Chronic myelogenous leukemia / Dermatofibrosarcoma protuberans / End point of clinical trials / Leukemia / Medicine / Oncology / Piperazines


PUBLIC SUMMARY DOCUMENT Product: Imatinib, tablet, 100 mg and 400 mg (as mesylate), GlivecĀ® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application
Add to Reading List

Document Date: 2014-10-01 21:56:22


Open Document

File Size: 130,64 KB

Share Result on Facebook
UPDATE